MedPath

Selective Omission of Sentinel Lymph Node Biopsy in Mastectomy for Ductal Carcinoma in Situ: Identifying Eligible Candidates

Completed
Conditions
Ductal Carcinoma in Situ
Interventions
Procedure: Mastectomy with sentinel lymph node biopsy
Registration Number
NCT05961280
Lead Sponsor
Gangnam Severance Hospital
Brief Summary

This study aimed to assess the prevalence of upgrade to invasive breast cancer and axillary lymph node metastasis in patients who were diagnosed with DCIS on biopsy and subsequently underwent mastectomy with axillary surgery to establish the need for SLNB. Furthermore, we explored the clinicopathologic features related to the upgrade to invasive breast cancer and axillary lymph node metastasis.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
385
Inclusion Criteria
  1. Women diagnosed with DCIS in preoperative biopsy samples obtained by core needle biopsy, vacuum-assisted breast biopsy, or excisional biopsy
  2. Women underwent curative surgery for DCIS
Exclusion Criteria
  1. Patients who received breast-conserving surgery
  2. Patients who had concurrent contralateral invasive breast cancer
  3. Patients who were in case of ipsilateral breast tumor recurrence
  4. Patients whose invasiveness was uncertain in the biopsy samples

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
DCIS MastectomyMastectomy with sentinel lymph node biopsyPatients who undergo mastectomy with sentinel lymph node biopsy for DCIS at biopsy
Primary Outcome Measures
NameTimeMethod
Axillary lymph node metastasis rateup to 2 weeks after surgery

Our primary objective was to identify the axillary lymph node metastasis rate in patients with DCIS at diagnosis who underwent mastectomy with axillary surgery.

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath